QV Investors Inc. Acquires 3,200 Shares of Haemonetics Corporation $HAE

QV Investors Inc. boosted its holdings in shares of Haemonetics Corporation (NYSE:HAE) by 28.5% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 14,440 shares of the medical instruments supplier’s stock after purchasing an additional 3,200 shares during the period. QV Investors Inc.’s holdings in Haemonetics were worth $1,077,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in HAE. Quarry LP lifted its stake in Haemonetics by 63.4% during the first quarter. Quarry LP now owns 495 shares of the medical instruments supplier’s stock worth $31,000 after purchasing an additional 192 shares during the last quarter. GAMMA Investing LLC lifted its stake in shares of Haemonetics by 59.4% in the 2nd quarter. GAMMA Investing LLC now owns 443 shares of the medical instruments supplier’s stock valued at $33,000 after acquiring an additional 165 shares during the last quarter. UMB Bank n.a. lifted its stake in shares of Haemonetics by 91.7% in the 2nd quarter. UMB Bank n.a. now owns 669 shares of the medical instruments supplier’s stock valued at $50,000 after acquiring an additional 320 shares during the last quarter. University of Texas Texas AM Investment Management Co. bought a new position in shares of Haemonetics in the 1st quarter valued at $65,000. Finally, CWM LLC lifted its stake in shares of Haemonetics by 53.5% in the 2nd quarter. CWM LLC now owns 1,827 shares of the medical instruments supplier’s stock valued at $136,000 after acquiring an additional 637 shares during the last quarter. 99.67% of the stock is currently owned by institutional investors.

Haemonetics Stock Performance

NYSE HAE opened at $51.24 on Friday. The company has a market capitalization of $2.47 billion, a price-to-earnings ratio of 15.67, a PEG ratio of 0.95 and a beta of 0.37. Haemonetics Corporation has a twelve month low of $47.31 and a twelve month high of $94.99. The stock has a fifty day simple moving average of $51.70 and a 200 day simple moving average of $62.43. The company has a quick ratio of 1.04, a current ratio of 1.72 and a debt-to-equity ratio of 1.04.

Haemonetics (NYSE:HAE) last posted its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $1.10 earnings per share for the quarter, beating analysts’ consensus estimates of $1.01 by $0.09. The business had revenue of $321.39 million during the quarter, compared to the consensus estimate of $305.12 million. Haemonetics had a return on equity of 26.64% and a net margin of 12.14%.Haemonetics’s quarterly revenue was down 4.4% on a year-over-year basis. During the same period in the prior year, the business posted $1.02 earnings per share. Haemonetics has set its FY 2026 guidance at 4.700-5.00 EPS. Sell-side analysts expect that Haemonetics Corporation will post 4.55 EPS for the current year.

Analyst Ratings Changes

A number of research analysts have recently commented on the company. Citigroup dropped their price target on Haemonetics from $78.00 to $64.00 and set a “buy” rating for the company in a research note on Tuesday, October 7th. JPMorgan Chase & Co. reiterated a “neutral” rating and issued a $62.00 price target (down from $85.00) on shares of Haemonetics in a research note on Friday, August 8th. Mizuho dropped their price target on Haemonetics from $90.00 to $70.00 and set an “outperform” rating for the company in a research note on Friday, August 8th. Needham & Company LLC reiterated a “buy” rating and issued a $68.00 price target (down from $84.00) on shares of Haemonetics in a research note on Thursday, August 7th. Finally, Raymond James Financial downgraded Haemonetics from a “strong-buy” rating to an “outperform” rating and decreased their price objective for the company from $105.00 to $78.00 in a report on Monday, August 11th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $75.89.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.